

Micotil™ 300

250 mL

(tilmicosin injection)

300 mg tilmicosin, USP as tilmicosin phosphate per mL

For Use in Cattle and Sheep Only

Solo Para Uso en Bovinos y Ovinos

Do Not Use in Automatically Powered Syringes.

No Administrar con Jeringas Accionadas Automáticamente.

Approved by FDA under NADA # 140-929

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description: Micotil is a solution of the antibiotic tilmicosin. Each mL contains 300 mg of tilmicosin, USP as tilmicosin phosphate in 25% propylene glycol, phosphoric acid as needed to adjust pH and water for injection, Q.S. Tilmicosin, USP is produced semi-synthetically and is in the macrolide class of antibiotics.

Indications: Micotil is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni* and for the treatment of ovine respiratory disease (ORD) associated with *Mannheimia haemolytica*. Micotil is indicated for the control of respiratory disease in cattle at high risk of developing BRD associated with *Mannheimia haemolytica*.

Dosage and Administration: Inject Subcutaneously in Cattle and Sheep Only.

In cattle, administer a single subcutaneous dose of 10 to 20 mg/kg of body weight (1 to 2 mL/30 kg or 1.5 to 3 mL per 100 lbs). **In sheep** greater than 15 kg, administer a single subcutaneous dose of 10 mg/kg of body weight (1 mL/30 kg or 1.5 mL per 100 lbs). Do not inject more than 10 mL per injection site.

If no improvement is noted within 48-hours, the diagnosis should be reevaluated.

For cattle and sheep, injection under the skin in the neck is suggested.

If not accessible, inject under the skin behind the shoulders and over the ribs.

Note: Swelling at the subcutaneous site of injection may be observed.

Contraindications: Do not use in automatically powered syringes. Do not administer intravenously to cattle or sheep. Do not use in lambs less than 15 kg body weight. Intravenous injection in cattle or sheep will be fatal. Do not administer to animals other than cattle or sheep. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and it may be fatal in horses and goats.

Warnings:

Human Warnings: Not for human use. Injection of this drug in humans has been associated with fatalities. Keep out of reach of children. Do not use in automatically powered syringes. Exercise extreme caution to avoid accidental self-injection. In case of human injection, consult a physician immediately and apply ice or cold pack to injection site while avoiding direct contact with the skin. Emergency medical telephone numbers are 1-800-722-0987 or 1-800-428-4441. Avoid contact with eyes.

Note To The Physician: The cardiovascular system is the target of toxicity and should be monitored closely. Cardiovascular toxicity may be due to calcium channel blockade. In dogs, administration of intravenous calcium offset Micotil-induced tachycardia and negative inotropy (decreased contractility). Dobutamine partially offset the negative inotropic effects induced by Micotil in dogs. β -adrenergic antagonists, such as propranolol, exacerbated the negative inotropy of Micotil in dogs. Epinephrine potentiated lethality of Micotil in pigs. This antibiotic persists in tissues for several days.

Advertencias Para El Ser Humano: Este producto no es para uso humano. La inyección de este medicamento al ser humano se ha asociado con muertes. Mantenga fuera del alcance de los niños. No use en jeringas operadas automáticamente. Proceda con extrema cautela para evitar la autoinyección accidental. En caso de inyección a un ser humano, consulte a un médico inmediatamente y aplique hielo o una bolsa de hielo sobre el sitio de la inyección, evitando el contacto directo con la piel. Los números de teléfono para emergencias médicas son 1-800-722-0987 ó 1-800-428-4441. Evite el contacto con los ojos.

Nota Para El Médico: El sistema cardiovascular es el blanco de la toxicidad y debe vigilarse estrechamente. La toxicidad cardiovascular puede deberse al bloqueo de los canales de calcio. En los perros, la administración intravenosa de calcio compensó la taquicardia y los efectos inotrópicos negativos (reducción de la contractilidad) inducidos por Micotil. La dobutamina compensó parcialmente los efectos inotrópicos negativos inducidos por Micotil en perros. Los antagonistas β -adrenérgicos, como propranolol, exacerbaron el inotropismo negativo de Micotil en los perros. La epinefrina potenció la letalidad de Micotil en cerdos. Este antibiótico persiste en los tejidos por varios días.

Residue Warnings: Animals intended for human consumption must not be slaughtered within 42 days of the last treatment. Not for use in lactating dairy cattle 20 months of age or older. Use of tilmicosin in this class of cattle may cause milk residues. Not for use in lactating ewes producing milk for human consumption.

For Subcutaneous Use in Cattle and Sheep Only.

Do Not Use in Automatically Powered Syringes.

Solo Para Uso Subcutáneo en Bovinos y Ovinos.

No Administrar con Jeringas Accionadas Automáticamente.

Precautions: Read accompanying literature fully before use. Intramuscular injection will cause a local reaction which may result in trim loss of edible tissue at slaughter.

The effects of tilmicosin on bovine and ovine reproductive performance, pregnancy and lactation have not been determined.

Adverse Reactions: The following adverse reactions have been reported post-approval:

In cattle: injection site swelling and inflammation, lameness, collapse, anaphylaxis/

anaphylactoid reactions, decreased food and water consumption, and death.

In sheep: dyspnea and death.

For additional information about reporting adverse drug experiences for animal drugs,

contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>

Clinical Pharmacology: A single subcutaneous injection of Micotil at 10 mg/kg of body weight dose in cattle resulted in peak tilmicosin levels within one hour and detectable levels

(0.07 μ g/mL) in serum beyond 3 days. However, lung concentrations of tilmicosin remained

above the tilmicosin MIC 95% of 3.12 μ g/mL for *Mannheimia haemolytica* for at least 3 days

following the single injection. Serum tilmicosin levels are a poor indicator of total body

tilmicosin. The lung/serum tilmicosin ratio in favor of lung tissue appeared to equilibrate by

3 days post-injection at approximately 60. In a study with radioactive tilmicosin, 24% and 68%

of the dose was recovered from urine and feces respectively over 21 days. After a single

subcutaneous injection of Micotil at 10 mg/kg of body weight, tilmicosin concentrations in

excess of 4 μ g/mL were maintained in the alveolar macrophages and neutrophils of most

cattle for at least 10 days. The clinical relevance of these findings has not been determined.

Microbiology: Tilmicosin has an *in vitro* antibacterial spectrum that is predominantly

Gram-positive with activity against certain Gram-negative microorganisms. *In vitro* activity

against several *Mycoplasma* species has also been observed.

Effectiveness: In a multi-location field study, 1508 calves with naturally occurring BRD

were treated with Micotil. Responses to treatment were compared to saline-treated controls.

A cure was defined as a calf with normal attitude and activity, normal respiration, and a

rectal temperature of <104°F on Day 13. The cure rate was significantly higher (P=0.004) in

Micotil-treated calves (63.1%) compared to saline-treated calves (29.2%). During the treatment

phase of the study, there were 10 BRD-related deaths in the Micotil-treated calves compared to

47 in the saline-treated calves.

Animal Safety: A safety study was conducted in feeder calves receiving subcutaneous doses

of 20, 30, 40, or 60 mg/kg of body weight, injected 3 times at 72-hour intervals. Death was not

seen in any of the treatment groups. Injection site swelling and mild hemorrhage at the injection

site were seen in animals in all dosage groups. Lesions were described as being generally more

severe and occurred at higher frequency rates in the animals treated with higher doses of

tilmicosin. Lameness associated with the injection site was noted in two of twenty-four animals

(one animal in the 30 mg/kg body weight treatment group and one animal in the 60 mg/kg

treatment group). No other drug related lesions were observed macroscopically or

microscopically. Decreases in food and water consumption were noted in all treatment groups

compared to the control group.

A separate safety study conducted in feeder calves, subcutaneous doses of 10, 30, or 50 mg/kg

of body weight, injected 3 times at 72-hour intervals did not cause any deaths. Edema at the site

of injection was noted. The only lesion observed at necropsy was minimal myocardial necrosis in

some animals dosed at 50 mg/kg.

In an additional safety study, subcutaneous doses of 150 mg/kg body weight injected at 72-hour

intervals resulted in death of two of the four treated animals. Edema was marked at the site of

injection. Minimal myocardial necrosis was the only lesion observed at necropsy. Deaths of

cattle have been observed with a single intravenous dose of 5 mg/kg of body weight.

In sheep, single subcutaneous injections of 10 mg/kg body weight dose did not cause any

deaths and no adverse effects of tilmicosin were observed on blood pressure, heart rate,

or respiratory rate.

Toxicology: The heart is the target of toxicity in laboratory and domestic animals given Micotil

by oral or parenteral routes. The primary cardiac effects are increased heart rate (tachycardia)

and decreased contractility (negative inotropy). Cardiovascular toxicity may be due to calcium

channel blockade.

Upon subcutaneous injection, the acute median lethal dose of tilmicosin in mice is 97 mg/kg,

and in rats is 185 mg/kg of body weight. Given orally, the median lethal dose is 800 mg/kg

and 2250 mg/kg body weight in fasted and nonfasted rats, respectively. No compound-related

lesions were found at necropsy.

In dogs, intravenous calcium offset Micotil-induced tachycardia and negative inotropy,

restoring arterial pulse pressure. Dobutamine partially offset the negative inotropic effects

induced by Micotil in dogs. β -adrenergic antagonists, such as propranolol, exacerbated the

negative inotropy of Micotil in dogs.

In monkeys, a single intramuscular dose of 10 mg/kg body weight caused no signs of toxicity.

A single dose of 20 mg/kg body weight caused vomiting and 30 mg/kg body weight caused

the death of the only monkey tested.

In swine, intramuscular injection of 10 mg/kg body weight caused increased respiration,

emesis, and a convulsion, 20 mg/kg body weight resulted in mortality in 3 of 4 pigs, and

30 mg/kg body weight caused the death of all 4 pigs tested. Injection of 4.5 and 5.6 mg/kg

body weight intravenously followed by epinephrine, 1 mL (1:1000) intravenously 2 to 6 times,

resulted in death of all pigs injected. Pigs given 4.5 mg/kg and 5.6 mg/kg body weight

intravenously with no epinephrine all survived. These results suggest intravenous epinephrine

may be contraindicated.

Results of genetic toxicology studies were all negative. Results of teratology and reproduction

studies in rats were negative. The no effect level in dogs after daily oral doses for up to one

year is 4 mg/kg of body weight.

Storage Conditions: Store at or below 86°F (30°C). Protect from direct sunlight.

Conservar a 86°F (30°C). Proteger de la luz solar directa.

To report adverse effects, access medical information, or obtain additional product information,

call 1-800-428-4441.

How Supplied: Micotil is supplied in 250 mL multi-dose amber glass bottles.

Manufactured for: **Elanco US, Inc.**

Greenfield, IN 46140, USA

Revised: March 2020

Micotil, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.